Atlas Trials

Metastatic Breast Cancer, HER2 Negative Primary Tumor

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Metastatic Breast Cancer, HER2 Negative Primary Tumor

RecordFirmDate
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment. (NCT01975142)Institut Curie2013-11-07

Track Metastatic Breast Cancer, HER2 Negative Primary Tumor automatically

Every clearance here is in the API, with alerts when new ones post.